GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axcella Health Inc (OTCPK:AXLA) » Definitions » ROIC %

Axcella Health (Axcella Health) ROIC % : -682.33% (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Axcella Health ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Axcella Health's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2023 was -682.33%.

As of today (2024-05-12), Axcella Health's WACC % is 12.59%. Axcella Health's ROIC % is -556.45% (calculated using TTM income statement data). Axcella Health earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Axcella Health ROIC % Historical Data

The historical data trend for Axcella Health's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axcella Health ROIC % Chart

Axcella Health Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROIC %
Get a 7-Day Free Trial -796.34 -1,365.48 -1,436.20 -1,566.12 -1,607.22

Axcella Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -815.67 -480.24 -617.49 -477.51 -682.33

Competitive Comparison of Axcella Health's ROIC %

For the Biotechnology subindustry, Axcella Health's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axcella Health's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axcella Health's ROIC % distribution charts can be found below:

* The bar in red indicates where Axcella Health's ROIC % falls into.



Axcella Health ROIC % Calculation

Axcella Health's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-72.799 * ( 1 - 0% )/( (4.329 + 4.73)/ 2 )
=-72.799/4.5295
=-1,607.22 %

where

Axcella Health's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2023 is calculated as:

ROIC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-14.172 * ( 1 - 0% )/( (2.278 + 1.876)/ 2 )
=-14.172/2.077
=-682.33 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axcella Health  (OTCPK:AXLA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Axcella Health's WACC % is 12.59%. Axcella Health's ROIC % is -556.45% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Axcella Health ROIC % Related Terms

Thank you for viewing the detailed overview of Axcella Health's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Axcella Health (Axcella Health) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 1270, Littleton, MA, USA, 01460
Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis.
Executives
Paul Fehlner officer: Senior Vice President, CIPO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
William Hinshaw director, officer: President and CEO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
L.p. Fpa, 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Fpa General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Societe Des Produits Nestle S.a. 10 percent owner AVENUE NESTLE 55, VEVEY V8 CH-1800
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Torben Straight Nissen director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Michael Rosenblatt director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martin Hendrix director C/O PROMETHEUS BIOSCIENCES, INC., 9410 CARROLL PARK DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Robert Crane officer: Chief Financial Officer 101 CONVENTION CENTER DRIVE SUITE 310, LAS VEGAS NV 89109